Chloroquine in cutaneous leishmaniasis
Keywords:
Cutaneous leishmaniasis, chloroquine, antimonialsAbstract
Background Chloroquine is an antiprotozoal drug that has shown a favorable therapeutic index for cutaneous leishmaniasis. Objective A clinical trial was conducted to determine the efficacy of oral chloroquine in patients with cutaneous leishmaniasis and its comparison with the most effective standard treatment, pentavalent antimony compounds. Patients and methods This non randomized, open-label comparison study was conducted in department of dermatology, Pakistan Institute of Medical Sciences,Islamabad, from August 2006 to January 2007. 30 patients, 12 years of age or older were enrolled in the study. Diagnosis was made on the basis of clinical features and histopathological examination. 15 patients received orally administered chloroquine 250mg tds for 20 days and remaining 15 patients received injectable pentavalent antimony 20mg/kg for 28 days. Pre-treatment complete physical examination was done along with necessary laboratory investigations in all cases. They were repeated after 2 weeks and then at the end of treatment to note any abnormality developing. Groups were almost matched in terms of age, duration of lesions and number of lesions. The efficacy was evaluated by the appearance of the lesion and healing with or without scar formation. Patients were followed up for 3 months. Results All patients completed the study without any complication. Lesions healed completely with only minimal scarring or post-inflammatory hyperpigmentation at the site of lesion. The cure rate at 3-month follow-up was 100% in group A (chloroquine) and 93% in group B (antimony compound) at the end of treatment period. Conclusion Chloroquine seems to be a safe and effective alternative to antimony compounds. The striking advantage of chloroquine being its benefit of oral administration, and low cost along with easy availability which is of particular importance in underdeveloped countries likePakistan.ÂReferences
Dedet JP, Pratlong F. Leishmaniasis. In: Manson P, Cook GC, Zumla A, eds. Manson's Tropical Diseases. 21st edn. London: WB Saunders; 2003. p. 1339-64.
Vega-Lopez F, Hay RJ. Leishmaniasis. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology, 7th edn. London: Blackwell Science; 2004. p. 32.35-47.
Bhutto AM, Soomro RA, Nonaka S, Hashiguchi Y. Detection of new endemic areas of cutaneous leishmaniasis in Pakistan: a 6-year study. Int J Dermatol 2003; 42: 543-8.
Yasinzai MM, Iqbal J, Kakar JK et al. Leishmaniasis in Pakistan: re-visited. J Coll Physicians Surg Pak 1996; 6: 70-2.
Rogers ME, Ilg T, Nikolaev AV et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature 2004; 430; 463-7.
Jaffernay M, Nighat R. Cutaneous leishmaniasis in Pakistan. Int J Dermatol 2001; 40: 159.
Ayub S, Gramiccia M, Khalid M et al. Cutaneous leishmaniasis in Multan: species identification. J Pak Med Assoc 2003; 53: 445-7.
Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment 2005, 44th edn. New York: McGraw-Hill; 2004.
Zvulunov A, Klaus S, Vardy D et al. Fluconazole for the treatment of cutaneous leishmaniasis. N Engl J Med 2002; 347: 370-1.
Alrajhi AA, Ibrahim EA, Devol EB et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.
Noor SM, Hussain D. Intralesional chloroquine in cutaneous leishmaniasis. J Pak Assoc Dermatol 2005; 15: 18-21.
Gurei MS, Tatli N, Ozbilge H et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 2000; 30: 169-76.
KroegerA, Avila EV, Morison L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: Cluster randomized trial. BMJ 2002; 325: 810-3.
Kolaczinski J, Brooker S, Reyburn H, Rowland M. Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in northwest Pakistan. Trans R Soc Trop Med Hyg 2004; 98: 373-8.
